drugset / Trial / NCT02947815

Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm

NCT02947815

Phase 2/3 Completed 234 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the Efficacy and Safety of NABOTA in treatment of essential blepharospasm

Timeline

Start
2016-10
Primary completion
2018-01
Completion
2018-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic